Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease

被引：39

作者：

Schapira, AHV

Olanow, CW

机构：

[1] Royal Free & Univ Coll Med Sch, Dept Clin Neurosci, UCL, London NW3 2PF, England

[2] UCL, Inst Neurol, London, England

[3] Mt Sinai Sch Med, Dept Neurol, New York, NY USA

来源：

ANNALS OF NEUROLOGY | 2003年 / 53卷

关键词：

D O I：

10.1002/ana.10514

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[No abstract available]

引用

页码：S149 / S157

页数：9

共 114 条

[1] Levodopa: why the controversy? [J].

Agid, Y ;

Olanow, CW ;

Mizuno, Y .

LANCET, 2002, 360 (9332) :575-575

[2] DOPAMINE-INDUCED PROTECTION OF STRIATAL NEURONS AGAINST KAINATE RECEPTOR-MEDIATED GLUTAMATE CYTOTOXICITY IN-VITRO [J].

AMANO, T ;

UJIHARA, H ;

MATSUBAYASHI, H ;

SASA, M ;

YOKOTA, T ;

TAMURA, Y ;

AKAIKE, A .

BRAIN RESEARCH, 1994, 655 (1-2) :61-69

[3]

ASANUMA M, 1995, ARCH INT PHARMACOD T, V329, P221

[4]

BASMA AN, 1995, J NEUROCHEM, V64, P825

[5] Bioenergetic approaches for neuroprotection in Parkinson's disease [J].

Beal, MF .

ANNALS OF NEUROLOGY, 2003, 53 :S39-S47

[6] CHRONIC TREATMENT WITH L-DOPA, BUT NOT BROMOCRIPTINE INDUCES DYSKINESIA IN MPTP-PARKINSONIAN MONKEYS - CORRELATION WITH [H-3] SPIPERONE BINDING [J].

BEDARD, PJ ;

DIPAOLO, T ;

FALARDEAU, P ;

BOUCHER, R .

BRAIN RESEARCH, 1986, 379 (02) :294-299

[7] SUPPRESSIVE EFFECT OF L-DOPA ON DOPAMINE CELLS REMAINING IN THE VENTRAL TEGMENTAL AREA OF RATS PREVIOUSLY EXPOSED TO THE NEUROTOXIN 6-HYDROXYDOPAMINE [J].

BLUNT, SB ;

JENNER, P ;

MARSDEN, CD .

MOVEMENT DISORDERS, 1993, 8 (02) :129-133

[8] Imaging end points for monitoring neuroprotection in Parkinson's disease [J].

Brooks, DJ .

ANNALS OF NEUROLOGY, 2003, 53 :S110-S118

[9] DOPAMINE AGONISTS IN PARKINSONS-DISEASE [J].

CALNE, DB ;

BURTON, K ;

BECKMAN, J ;

MARTIN, WRW .

CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1984, 11 (01) :221-224

[10]

Camp DM, 2000, J NEUROCHEM, V74, P1229

← 1 2 3 4 5 6 7 8 9 10 →